Grufity logo
Grufity logo
RVPH

RVPH - Reviva Pharmaceuticals Holdings Stock Price, Fair Value and News

$0.70+0.02 (+2.94%)
Market Closed as of 15 Jun 2026, 04:00 pm ET

Price Targets

RVPH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RVPH Price Action

Last 7 days

-4.2%

Last 30 days

94.3%

Last 90 days

-72.5%

Trailing 12 Months

-95.6%

RVPH RSI Chart

RVPH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RVPH Valuation

Market Cap

9.0M

Price/Earnings (Trailing)

-0.54

Price/Sales (Trailing)

11.04

EV/EBITDA

0.8

Price/Free Cashflow

-0.44

RVPH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

RVPH Fundamentals

RVPH Revenue

Revenue (TTM)

499.0K

RVPH Earnings

Earnings (TTM)

-16.6M

Earnings Growth (Yr)

50.32%

Earnings Growth (Qtr)

5.1%

RVPH Profitability

EBT Margin

-3329.10%

Return on Equity

-95.34%

Return on Assets

-70.58%

Free Cashflow Yield

-225.28%

RVPH Investor Care

Shares Dilution (1Y)

448.16%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2023---499.0K
2022-131.1K156.9K182.8K
2020---105.2K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Reviva Pharmaceuticals Holdings

RVPH
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.
 CEO
 WEBSITEhttps://revivapharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES10

Reviva Pharmaceuticals Holdings Frequently Asked Questions

RVPH is the stock ticker symbol of Reviva Pharmaceuticals Holdings. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Reviva Pharmaceuticals Holdings is 8.97 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, RVPH's PE ratio (Price to Earnings) is -0.54 and Price to Sales (PS) ratio is 11.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RVPH PE ratio will change depending on the future growth rate expectations of investors.